Ying Chen1, Muxing Kang, Wenjie Lu, Qingqu Guo, Bo Zhang, Qiuping Xie, Yulian Wu. 1. Department of Surgery, Second Affiliated Hospital, College of Medicine, Cancer Institute of Zhejiang University, Zhejiang University, #88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, People's Republic of China.
Abstract
PURPOSE: Aberrant expression of DJ-1 has been proven to be associated with tumorigenesis in many carcinomas. However, its role in pancreatic cancer is unknown. The aims of this study were to investigate whether the serum DJ-1 might be a potential biomarker for pancreatic cancer and to determine the biologic function of DJ-1 expression in gemcitabine-induced chemoresistance of pancreatic cancer. METHODS: The serum level of DJ-1 was higher in 128 pancreatic cancer patients compared with 62 healthy controls by ELISA. To determine the effect of DJ-1 on pancreatic tumor chemoresistance, a siRNA-targeting DJ-1 was synthesized and a stably transfected cell line with DJ-1 over-expression was constructed. The mechanism of tumor chemoresistance was assessed by multiple methods, such as MTT assay, real-time PCR, Western blot and flow cytometry. RESULTS: The serum level of DJ-1 was higher in pancreatic cancer patients than healthy controls, and it has the relationship with tumor differentiation in pancreatic cancer. Down-regulation of DJ-1 enhanced gemcitabine-induced apoptosis in three pancreatic cancer cell lines. On the contrary, over-expression of DJ-1 desensitized the MIA PaCa-2 to the induction of apoptosis by gemcitabine. CONCLUSIONS: Our results suggest that the serum level of DJ-1 may be a potential biomarker for pancreatic cancer, and that DJ-1 plays critical roles in the pancreatic tumor chemoresistance, supporting the development of chemotherapeutic approaches targeting this oncogene.
PURPOSE: Aberrant expression of DJ-1 has been proven to be associated with tumorigenesis in many carcinomas. However, its role in pancreatic cancer is unknown. The aims of this study were to investigate whether the serum DJ-1 might be a potential biomarker for pancreatic cancer and to determine the biologic function of DJ-1 expression in gemcitabine-induced chemoresistance of pancreatic cancer. METHODS: The serum level of DJ-1 was higher in 128 pancreatic cancerpatients compared with 62 healthy controls by ELISA. To determine the effect of DJ-1 on pancreatic tumor chemoresistance, a siRNA-targeting DJ-1 was synthesized and a stably transfected cell line with DJ-1 over-expression was constructed. The mechanism of tumor chemoresistance was assessed by multiple methods, such as MTT assay, real-time PCR, Western blot and flow cytometry. RESULTS: The serum level of DJ-1 was higher in pancreatic cancerpatients than healthy controls, and it has the relationship with tumor differentiation in pancreatic cancer. Down-regulation of DJ-1 enhanced gemcitabine-induced apoptosis in three pancreatic cancer cell lines. On the contrary, over-expression of DJ-1 desensitized the MIA PaCa-2 to the induction of apoptosis by gemcitabine. CONCLUSIONS: Our results suggest that the serum level of DJ-1 may be a potential biomarker for pancreatic cancer, and that DJ-1 plays critical roles in the pancreatic tumor chemoresistance, supporting the development of chemotherapeutic approaches targeting this oncogene.
Authors: Raymond H Kim; Malte Peters; YingJu Jang; Wei Shi; Melania Pintilie; Graham C Fletcher; Carmela DeLuca; Jennifer Liepa; Lily Zhou; Bryan Snow; Richard C Binari; Armen S Manoukian; Mark R Bray; Fei-Fei Liu; Ming-Sound Tsao; Tak W Mak Journal: Cancer Cell Date: 2005-03 Impact factor: 31.743
Authors: Darren J Moore; Li Zhang; Juan Troncoso; Michael K Lee; Nobutaka Hattori; Yoshikuni Mizuno; Ted M Dawson; Valina L Dawson Journal: Hum Mol Genet Date: 2004-11-03 Impact factor: 6.150
Authors: Zhongkui Li; Guido M Sclabas; Bailu Peng; Kenneth R Hess; James L Abbruzzese; Douglas B Evans; Paul J Chiao Journal: Cancer Date: 2004-07-01 Impact factor: 6.860
Authors: Canan Schumann; Stephanie Chan; Jess A Millar; Yuliya Bortnyak; Katherine Carey; Alex Fedchyk; Leon Wong; Tetiana Korzun; Abraham S Moses; Anna Lorenz; Delany Shea; Olena Taratula; Oleh Khalimonchuk; Oleh Taratula Journal: Nanomedicine Date: 2018-04-07 Impact factor: 5.307